임뮤텝 (IMMP) 주가

임뮤텝(IMMP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.38 (-5.82%), 시가총액 $0.07B, 52주 범위 $0.31 ~ $3.18.

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinom

핵심 지표

• 현재가: $0.38 (-5.82%)
• 시가총액: $0.07B
• 52주 최저~최고: $0.31 ~ $3.18
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

임뮤텝의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

임뮤텝 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.92
• 순이익률: 0.00%
• 영업이익률: -7.64%

자주 묻는 질문